Answers are grounded in this paper and cite their sources.
Currently there are no generally accepted criteria for patient selection for surgery within a multimodality treatment protocol, but patient selection remains the key parameter for surgical success and low morbidity and mortality. Among clinical, pathologic, and molecular prognostic factors studied in the past, the combination of several factors seems to be the most appropriate tool for decision-making, including also institutional experience and availability of therapy as well as factors such as the patient’s choice of treatment. Preoperative identification of benefit from surgery comprising a summary of interdisciplinary preoperative workup includes many aspects in this decision-making process, including exact diagnosis, staging, validated prognostic scores, multimodal therapy options based on recommendations of the multidisciplinary tumor board, and prospective evaluation of these treatment allocation protocols, when selecting the appropriate therapy for patients in the future. In appropriately selected patients with an acceptable risk profile, surgical resection (extended P/D, P/D, or EPP) as part of a multimodality concept should still be offered if performed in high-volume and low-mortality centers, and in any case inclusion in clinical trials or large national or international registries is recommended.
No takes yet. Share an insight, caveat, or question.
Opitz et al. (2020) studied this question.
Synapse has enriched 6 related papers. Consider them for comparative context: